# Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 1 and Cohort 2)

> **NCT02601313** · PHASE2 · COMPLETED · sponsor: **Kite, A Gilead Company** · enrollment: 105 (actual)

## Conditions studied

- Relapsed/Refractory Mantle Cell Lymphoma

## Interventions

- **BIOLOGICAL:** brexucabtagene autoleucel
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **DRUG:** Axicabtagene Ciloleucel

## Key facts

- **NCT ID:** NCT02601313
- **Lead sponsor:** Kite, A Gilead Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11-09
- **Primary completion:** 2023-09-22
- **Final completion:** 2023-09-22
- **Target enrollment:** 105 (ACTUAL)
- **Last updated:** 2026-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02601313

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02601313, "Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 1 and Cohort 2)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02601313. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*